Highly Efficient Olefin-Metathesis Catalysts - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Highly Efficient Olefin-Metathesis Catalysts
The authors describe the Piers' catalysts and detail latest progress in olefin-metathesis catalyst technology.


Pharmaceutical Technology


7. S.R. Dubberley et al., "Synthesis, Characterization and Olefin Metathesis Studies of a Family of Ruthenium Phosphonium Alkylidene Complexes," Inorg. Chim. Acta. 359 (9), 2658–2664 (2006).

8. P.E. Romero and W.E. Piers, "Direct Observation of a 14-Electron Ruthenacyclobutane Relevant to Olefin Metathesis," J. Am. Chem. Soc. 127 (14), 5032–5033 (2005).

9. C. W. Lee et al., "Impurity Reduction in Olefin Metathesis Reactions," US Patent Application US2005/0203324 A1 (Priority Date Aug. 23, 2004, released Sept. 15, 2005).

10. B.P. Paulson and R.L. Pederson, "Impurity Inhibition in Olefin-Metathesis Reactions," US Patent 6,900,347, issued May 31, 2005.

11. R.L. Pederson and B. P. Paulson, "Impurity Inhibition in Olefin-Metathesis Reactions," WO 02094748, A1 Priority Date May 24, 2001.

12. R.L. Pederson et al., "Applications of Olefin Cross Metathesis to Commercial Products," Adv. Synth. Catal. 344 (6–7), 728–735 (2002).

13. K.C. Nicolaou, A. Ortiz, and R.M. Denton, "Metathesis Reaction in the Synthesis of Complex Molecules," Chem. Today 25 (5), 70–76 (2007).

14. D.J. Wallace et al., "A Double Ring Closing Metathesis Reaction in the Rapid, Enantioselective Synthesis of NK-1 Receptor Antagonists," Org. Lett. 3 (5), 671–674 (2001).

15. R.M. Kanada et al., "Total Synthesis of the Potent Antitumor macrolides Pladienolide B and D," Angew. Chem., Int. Ed. 46 (23), 4350–4355 (2007).

16. P. Schwab, R.H. Grubbs, and J.W. Ziller, "Synthesis and Applications of RuCl2 (=CHR')(PR3)2: The Influence of the Alkylidene Moiety on Metathesis Activity," J. Am. Chem. Soc. 118 (1), 100–110 (1996).

17. M. Scholl, S. Ding, C.W. Lee, and R.H. Grubbs, "Synthesis and Activity of a New Generation of Ruthenium-Based Olefin Metathesis Catalysts Coordinated with 1,3-Dimesityl-4,5-dihydroimidazole-2-ylidene Ligands," Org. Lett. 1 (6), 953–956 (1999).

18. S.B. Garber et al., "Efficient and Recyclable Monomeric and Dendritic Ru-Based Metathesis Catalysts," J. Am. Chem. Soc. 122 (34), 8168–8179 (2000).

19. I.C. Stewart et al., "Highly Efficient Ruthenium Catalysts for the Formation of Tetrasubstituted Olefins via Ring-Closing Metathesis," Org. Lett. 9 (8), 1589–1592 (2007).

20. C.K. Chung and R.H. Grubbs, "Olefin Metathesis Catalyst: Stabilization Effect of Backbone Substitutions of N -Heterocyclic Carbene," Org. Lett. 10 (13), 2693–2692 (2008).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Source: Pharmaceutical Technology,
Click here